CurrentEndo
Get Weekly

Topic · page 19 of 35

Osteoporosis, bone & mineral

Osteoporosis in women and men, fracture risk and bone density, fragility fractures and their secondary prevention, bone drugs and treatment sequence; hyperparathyroidism and hypoparathyroidism, vitamin D, calcium and phosphate disorders, rare metabolic bone disease

Briefs 721–760 of 1,367 placed here, newest publication first

Briefs in Osteoporosis, bone & mineral

Newest publication first

  1. Horm Res Paediatr

    Characterization of Digestive Manifestations in Patients with Impaired PTH/PTHrP Signaling Disorder/Pseudohypoparathyroidism

    Cross-sectional study

  2. J Bone Miner Res

    Male–female spatio-temporal differences of age-related bone changes show faster bone deterioration in older women at femoral regions associated with incident hip fracture

    Cohort study

  3. J Clin Endocrinol Metab

    Alteration of Bone Microarchitecture in Hereditary Distal RTA Patients With SLC4A1 Gene Mutation: Assessed by HR-pQCT

    Cohort study

  4. Osteoporos Int

    An electronic health record (EHR)-based risk calculator can predict fractures comparably to FRAX: a proof-of-concept study

    Diagnostic or prognostic study

  5. Osteoporos Int

    Fracture risk assessment in the presence of competing risk of death

    Diagnostic or prognostic study

  6. J Clin Endocrinol Metab

    Association of Serum 25-Hydroxyvitamin D With Stroke: Observational Mediation and Mendelian Randomization Study

    Cohort study

  7. J Bone Miner Res

    Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia

    Research article

  8. Clin Endocrinol (Oxf)

    Daily versus fortnightly oral vitamin D 3 in treatment of symptomatic vitamin D deficiency in children aged 1−10 years: An open labelled randomized controlled trial

    Randomized controlled trial

  9. Osteoporos Int

    Association of proton-density fat fraction with osteoporosis: a systematic review and meta-analysis

    Meta-analysis

  10. J Clin Endocrinol Metab

    Increased Risk of Chronic Kidney Disease After Total Thyroidectomy: A Nationwide Matched Cohort Study

    Cohort study

  11. J Bone Miner Res

    Gene-based association analysis of a large patient cohort provides insights into genetics of atypical femur fractures

    Case-control study

  12. J Bone Miner Res

    Multi-omics analyses reveal aberrant differentiation trajectory with WNT1 loss-of-function in type XV osteogenesis imperfecta

    Cohort study

  13. Osteoporos Int

    Assessing the causal relationship between plasma proteins and osteoporosis: novel insights into pathological mechanisms and therapeutic implications

    Research article

  14. Eur J Endocrinol

    Metabolically healthy obesity in adults with X-linked hypophosphatemia

    Cohort study

  15. Osteoporos Int

    The Healing and therapeutic effects of perioperative bisphosphonate use in patients with fragility fractures: meta-analysis of 19 clinical trials

    Meta-analysis

  16. Osteoporos Int

    One versus 2 years of alendronate following denosumab: the CARD extension

    Randomized controlled trial

  17. Clin Endocrinol (Oxf)

    Trabecular bone score norms in Asian‐Indians and associations with serum 25(OH)D and parathyroid hormone

    Cross-sectional study

  18. Osteoporos Int

    Sarcopenia definitions and their association with injurious falls in older Swedish women from the Sahlgrenska University Hospital Prospective Evaluation of Risk of Bone fractures (SUPERB) study

    Cohort study

  19. J Bone Miner Res

    The relationship between treatment-related changes in total hip BMD measured after 12, 18, and 24 mo and fracture risk reduction in osteoporosis clinical trials: the FNIH-ASBMR-SABRE project

    Meta-analysis

  20. Osteoporos Int

    Real-world efficacy of a teriparatide biosimilar (RGB-10) compared with reference teriparatide on bone mineral density, trabecular bone score, and bone parameters assessed using quantitative ultrasound, 3D-SHAPER® and high-resolution peripheral computer tomography in postmenopausal women with osteoporosis and very high fracture risk

    Cohort study

  21. Osteoporos Int

    Sex differences and predictors of anti-osteoporosis medication use in the 12 months after hip fracture surgery in adults 65 or older

    Cohort study

  22. Osteoporos Int

    The diagnostic value of MRI-based vertebral bone quality score for osteoporosis or osteopenia in patients undergoing lumbar surgery: a meta-analysis

    Meta-analysis

  23. Osteoporos Int

    Group-based trajectories of potentially preventable hospitalisations among older adults after a hip fracture

    Cohort study

  24. Osteoporos Int

    Risk factors associated with 1-year mortality after osteoporotic hip fracture in Hawaiʻi: higher mortality risk among Native Hawaiians and other Pacific Islanders

    Cohort study

  25. Eur J Endocrinol

    Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies

    Cohort study

  26. J Clin Endocrinol Metab

    Cystinosis-Associated Metabolic Bone Disease Across Ages and CKD Stages 1 to 5D/T

    Cross-sectional study

  27. J Bone Miner Res

    Structural and molecular imaging-based characterization of soft tissue and vascular calcification in hyperphosphatemic familial tumoral calcinosis

    Cohort study

  28. Osteoporos Int

    Type 2 diabetes incidence in patients initiating denosumab or alendronate treatment: a primary care cohort study

    Cohort study

  29. Osteoporos Int

    Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis

    Randomized controlled trial

  30. J Bone Miner Res

    Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension

    Secondary analysis

  31. Clin Endocrinol (Oxf)

    Higher risk of incident diabetes among patients with primary hyperparathyroidism

    Cohort study

  32. Osteoporos Int

    Longitudinal assessment of physical function in adults with X-linked hypophosphatemia following initiation of burosumab therapy

    Cohort study

  33. J Bone Miner Res

    Evaluation of romosozumab’s effects on bone marrow adiposity in postmenopausal osteoporotic women: results from the FRAME bone biopsy sub-study

    Secondary analysis

  34. J Bone Miner Res

    Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study

    Randomized controlled trial

  35. J Clin Endocrinol Metab

    The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis

    Cohort study

  36. Osteoporos Int

    Non-osteoporotic fractures are associated with increased risk of subsequent major osteoporotic fractures

    Cohort study

  37. J Bone Miner Res

    High physical activity is associated with greater cortical bone size, better physical function, and with lower risk of incident fractures independently of clinical risk factors in older women from the SUPERB study

    Cohort study

  38. J Bone Miner Res

    Following hip fracture, hospital organizational factors associated with prescription of anti-osteoporosis medication on discharge, to address imminent refracture risk: a record-linkage study

    Cohort study

  39. Osteoporos Int

    Artificial intelligence-enhanced opportunistic screening of osteoporosis in CT scan: a scoping Review

    Research article

  40. J Bone Miner Res

    Bone matrix properties in adults with osteogenesis imperfecta are not adversely affected by setrusumab—a sclerostin neutralizing antibody

    Mechanistic study

All 1,367 Briefs in ExploreShowing Briefs 721–760 of 1,367, newest first